Comparison between upfront surgery and neoadjuvant chemotherapy in patients with locally advanced gastric cancer: A systematic review

Table 4 Morbidity and mortality of patients after neoadjuvant chemotherapy and surgery versus upfront surgery

Ref.	Morbidity		P value	Mortality		P value
	NAT	US		NAT	US
Ahn et al[8], 2014	22.9%	29.3%		0	2.1%
Biondi et al[9], 2018	21.4%	12.9%	0.178	0	3.7%
Bracale et al[10], 2021	38.1%	21.6%	0.019	0	2.1%
Eom et al[11], 2018	14.3%	15.1%	0.999	0	0
Feng et al[12], 2015	18.8%	22.2%	0.704	NS	NS
Wang et al[13], 2021	23.1%	30%	0.56	NS	NS
Xue et al[14], 2018	30%	28%	0.986	2%	2%
Kang et al[15], 2021	8.1%	5.5%	0.175	0.4%
Kano et al[16], 2019	23.1%	40.5%	0.101	NS	NS
Lin et al[17], 2022	NS	NS		NS	NS
Marino et al[18], 2021	Less than US		> 0.05	NS	NS
Molina et al[19], 2013	-	5%		-	2.5%
Pardo et al[20], 2020	11.5%	9.9%	0.268	2.8%	5.3%	0.142
Wang et al[21], 2019	9%	17%	0.519	0	0
Wang et al[22], 2021	6.4%	0		0.2%	0
Wu et al[23], 2019	10.5%	15.1%	0.361	0	0
Xu et al[24], 2021	6.79%	12.67%	0.037	n = 172 in total
Zhao et al[25], 2017	14%	15.4%	0.844	0	0

NAT: Neoadjuvant chemotherapy; US: Upfront surgery; NS: Not stated.